Europe's Pharma Scene Is Bleeding Out (and Nobody's Stitching the Wound)

Why the Capital (and the Talent) Keep Leaving

So what's actually pushing investment out of Europe? The executives pointed to a familiar cocktail of problems: slower approval pathways, fragmented regulations, and health systems that arbitrarily cap budgets for innovative medicines.

Start with the trial problem. Running a clinical trial in Europe means navigating a patchwork of national systems, each with its own timelines and requirements. In the U.S., you deal with one FDA. In Europe, you deal with 27 member states that technically harmonized their rules but still execute at wildly different speeds. For a drugmaker deciding where to run a pivotal trial, the math isn't complicated: go where you can enroll patients faster and get to market sooner.

Then there's the market access issue. The pharma chairs said about 40% of newly approved therapies never reach European patients because pricing and reimbursement processes are too slow or too restrictive. That's not just a patient access problem; it's a signal to investors. If you can't sell your drug effectively in a market, why would you develop it there?

This creates a vicious cycle. Less investment means fewer trials. Fewer trials means less infrastructure. Less infrastructure means even less investment. The talent follows the money, and the money follows the speed.

Brussels Has a Plan (Industry Says It's Not Enough)

The European Commission isn't ignoring the problem. It launched what it calls the largest reform of EU pharmaceutical legislation in over 20 years, with goals that include cutting red tape, speeding up drug authorizations, and creating a more "innovation-friendly environment." The reform package also includes targeted policies for earlier entry of generics and biosimilars, alongside competition enforcement measures.

On paper, it sounds promising. In practice, the industry's trade group EFPIA has been blunt: the package "is not strong enough to move the needle" on European competitiveness. That's a diplomatic way of saying the prescription doesn't match the severity of the disease.

The executives' wish list is specific. They want faster trials, stronger intellectual property protections, and what they call "fiscal flexibility": basically, governments loosening the purse strings on health spending so innovative medicines can actually reach patients who need them.

Why This Matters Beyond Europe

You might be thinking: "I'm not European. Why should I care?"

Because this is really a story about where the next generation of medicines gets built. When a continent that once led global pharma innovation starts losing its talent pipeline, the entire ecosystem shifts. Clinical trials move. Manufacturing follows. Expertise concentrates in fewer places.

For U.S. and Asian biotech, the short-term effect might feel positive: more investment flowing your way, more talent available, more trial sites competing for your business. But a less competitive Europe also means a less diverse global R&D landscape. Concentration risk isn't just a portfolio management concept; it applies to drug development too.

And for European patients, the consequences are already here. When 40% of approved therapies never make it to your hospital, "competitiveness" stops being an abstract policy debate and becomes a question of whether your doctor can prescribe the treatment that might save your life.

The Bottom Line

Europe's pharma decline didn't happen overnight, and it won't reverse overnight either. The drop from 43% to 31% of global R&D took 35 years. The clinical trial share got cut in half in just ten.

The open letter from nine pharma chairs is unusual not because of what it says (industry always wants friendlier policies) but because of who's saying it together. These companies compete fiercely with each other on everything from oncology to obesity drugs. When they all agree the roof is leaking, it's worth checking for water damage.

Europe still has world-class science, deep regulatory expertise, and some of the biggest pharma companies on the planet headquartered on its soil. But the gap between having great ingredients and running a great restaurant is execution. Right now, the diners are heading elsewhere.

GSK Thinks It Can Build a Better Flu Shot With mRNA

GSK's mRNA flu vaccine just beat both standard and high-dose flu shots in a mid-stage trial of 971 adults. Now it's heading to Phase 3, putting GSK squarely in Moderna's rearview mirror in the race to reinvent the annual flu shot.